Meeting
2022 ASCO Annual Meeting
A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).
Authors
Wafik S. El-Deiry
Cancer Center at Brown University, Providence, RI
Wafik S. El-Deiry , Taylor Arnoff , Ilyas Sahin , Hossein Borghaei , Vivek Subbiah , Hina Khan , Benedito A. Carneiro , Howard Safran , Stephanie L. Graff , Don S. Dizon , Elisabeth I. Heath , Eric T. Wong , Abbas Abbas , Christopher G. Azzoli , Michael J. Demeure , Jim Abraham , Razelle Kurzrock , Joanne Xiu , Emil Lou , Stephen V. Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2630)
DOI
10.1200/JCO.2022.40.16_suppl.2630
Abstract #
2630
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).
First Author: Natalie Ngoi
Poster
2020 ASCO Virtual Scientific Program
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Jia Luo
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
First Author: Benjamin Herzberg